HYPOTENSIVE EFFECT OF RENAL DENERVATION AND ITS IMPACT ON LEFT VENTRICULAR HYPERTROPHY SEVERITY
https://doi.org/10.29001/2073-8552-2016-31-2-15-18
Abstract
The aim of the study was to evaluate long-term antihypertensive and cardioprotective efficacy of renal denervation in patients with drug(resistant arterial hypertension. The study excluded patients with symptomatic hypertension, multiple renal arteries when the diameter of one or more arteries was less than 3 mm, and patients with severe kidney disease stage 4–5. According to these criteria, 73 people were selected for renal denervation procedure. Comparison of the initial data with the values obtained after 12 months demonstrated the presence of a significant continuous antihypertensive effect with blood pressure decrease by –29.1/–14.8 mm Hg in the office blood pressure levels and by –12.9/–7.8 mm Hg according to 24(h monitoring. The study showed a decrease in the myocardial mass of the left ventricle in individuals who initially had more pronounced left ventricular hypertrophy.
About the Authors
V. A. LichikakiRussian Federation
V. F. Mordovin
Russian Federation
S. E. Pekarsky
Russian Federation
T. M. Ripp
Russian Federation
A. Yu. Falkovskaya
Russian Federation
A. E. Baev
Russian Federation
T. R. Ryabova
Russian Federation
G. V. Semke
Russian Federation
I. V. Zyubanova
Russian Federation
References
1. Mancia G., Fagard R., Narkiewicz K. Guidelines 2013 ESH/ESC for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. – 2013. – Vol. 31, No. 7. – P. 1281–1357.
2. Мордовин В.Ф., Пекарский С.Е., Семке Г.В. и др. Использова( ние современных медицинских технологий для диагнос( тики и лечения больных артериальной гипертонией // Сибирский медицинский журнал (Томск). – 2015. – Т. 30, № 2. – С. 29–35.
3. Catheter(based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months / Symplicity HTN(1 Investigators // Hypertension. – 2011. – Vol. 57, No. 5. – P. 911–917.
4. Кузнецова Т.Ю., Гаврилов Д.В., Самоходская Л.М. и др. Ассо( циация клинических и генетических факторов с гиперт( рофией левого желудочка при артериальной гипертонии / / РФК. – 2010. – Т. 6, № 3. – С. 294–304.
5. Levy D., Salomon M., D’Agostino R.B. et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy // Circulation. – 1994. –Vol. 90(4). – P. 1786–1793.
6. Конради А.О. Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка // Арте( риал. гипертен. – 2005. – Т. 11, № 2. – С. 105–110.
7. Рипп Т.М., Мордовин В.Ф., Пекарский С.Е. Кардиопротектив( ные возможности денервации почек при лечении резис( тентной гипертонии, поиск предикторов эффективности // Артериал. гипертен. – 2014. – Т. 20, № 6. – С. 559–567.
8. Копылов Ф.Ю., Иванов Г.Г. и др. Гипертрофия левого желу( дочка: патогенез, диагностика и прогноз // Вестн. РУДН, серия “Медицина”. – 2002. – № 4. – С. 106–124.
Review
For citations:
Lichikaki V.A., Mordovin V.F., Pekarsky S.E., Ripp T.M., Falkovskaya A.Yu., Baev A.E., Ryabova T.R., Semke G.V., Zyubanova I.V. HYPOTENSIVE EFFECT OF RENAL DENERVATION AND ITS IMPACT ON LEFT VENTRICULAR HYPERTROPHY SEVERITY. Siberian Journal of Clinical and Experimental Medicine. 2016;31(2):15-18. (In Russ.) https://doi.org/10.29001/2073-8552-2016-31-2-15-18